Latest News
-

Huntingtin grabs a hammer: DNA repair in HD
Huntingtin helps fix damaged DNA, a recent study suggests, under the direction of a gene repair protein called ATM.
-

The benefits of migration, highlighted in Huntington's disease
Is HD a developmental disease? HD stops neurons migrating in developing brain, but maybe we can get them going again
-

Treasure your exceptions – using outliers to understand Huntington's disease onset and progression
A new study provides the framework for finding factors that affect the onset and progression of HD
-

A powerful message: does a toxic RNA message molecule cause harm in Huntington's disease?
What if some problems in HD were due to something other than a harmful protein?
-

Pfizer Amaryllis trial ends in disappointment: no improvement in Huntington's disease symptoms
Pfizer announces the 'Amaryllis' trial of a PDE-10 inhibitor drug failed to improve symptoms of HD
-

Important advances in next generation genome editing tools for Huntington's Disease
Work with genome editing techniques (zinc fingers and CRISPR) brings these tools closer to use in HD clinical trials
-

Sorry folks, the PRIDE-HD trial did NOT show that Pridopidine slows the progression of Huntington's disease
HDBuzz helps untangle some bold claims about the just-announced results of the PRIDE-HD trial of pridopidine in HD
-

EuroBuzz 2016: The Euro-HD Network Meeting in The Hague
All our tweets from #EHDN2016 in one mega-article
-

Ultra-rare mutations highlight the importance of the HD gene in brain development
New technology enables researchers to find ultra-rare mutations in the HD gene, distinct from the one causing HD
-

A support system gone wrong – glial cells contribute to HD symptoms
An elegant new study helps determine how much brain cells called glia matter to HD symptoms
HDBuzz Trial Tracker
Sites for Phase 3 trial for votoplam, INVEST-HD, now open. Updates on recruitment and first dosing imminent.
REGEN4HD, Phase 1 stem cell implantation study commences
Progress update for NCT06585449 – A Study to Evaluate ALN-HTT02
Updates from the ongoing placebo-controlled Phase 2/3 FALCON-HD trial
Previously featured
-
Fixing the Recipe: Lowering a Slice of Huntingtin
-
Tagging the Trash: Turnover of Toxic Huntingtin
-
Prilenia’s Application for European Approval of Pridopidine Withdrawn
-
Intruders in the Brain: What a Pig Model Reveals about Immune Cells in HD
-
The Great Care Conundrum: What “Good” Care Looks Like in Huntington’s Disease
Follow HDBuzz
Sign up to our monthly email summary by entering your email address on our mailing list page.
Suggest an article
Is there something you want us to write about? Tell us about it here. We consider all suggestions but can’t promise to write content about any particular suggestion.
